Trials / Withdrawn
WithdrawnNCT05238532
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS
A Multi-center, Open-label Dose-escalation and Dose-finding Phase I Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Acute Respiratory Distress Syndrome
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GC Cell Corporation · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety, tolerability, efficacy and pharmacodynamics\&pharmacokinetic properties of CT303 in patients with ARDS.
Detailed description
This study is a multi-center, open-label, dose-escalation and dose-finding phase 1 clinical trial. The primary purpose is to evaluate the safety and tolerability of CT303 and the Secondary purpose is to evaluate the efficacy of CT303 in patients with ARDS. And the exploratory purpose is to evaluate pharmacodynamics properties pharmacokinetic properties of CT303 in patients with ARDS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | CT303 | Once a time, intravenous injection * CT303 Starting Dose : 1.0\*10\^6 cells/kg * CT303 Increasing Quantity Dose : 2.0\*10\^6 cells/kg |
Timeline
- Start date
- 2022-01-26
- Primary completion
- 2023-02-22
- Completion
- 2023-02-22
- First posted
- 2022-02-14
- Last updated
- 2023-04-04
Locations
3 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05238532. Inclusion in this directory is not an endorsement.